Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To the Editor: Dr Gallant and colleagues1 compared the proportion of patients with HIV RNA levels
less than 400 copies/mL at week 48 in antiretroviral-naive patients who randomly
received either tenofovir or stavudine, in combination with efavirenz and
lamivudine. The authors stated in their methods that “the study was
designed as a noninferiority trial (ie, equivalence).” However, noninferiority
and equivalence hypotheses are not identical.
Parienti J. Tenofovir, Equivalence, and Noninferiority. JAMA. 2004;292(16):1951-1952. doi:10.1001/jama.292.16.1951-a